Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity

Gut microbiota, specifically gut bacteria, are critical for effective immune checkpoint blockade therapy (ICT) for cancer. The mechanisms by which gut microbiota augment extraintestinal anticancer immune responses, however, are largely unknown. Here, we find that ICT induces the translocation of specific endogenous gut bacteria into secondary lymphoid organs and subcutaneous melanoma tumors. Mechanistically, ICT induces lymph node remodeling and dendritic cell (DC) activation, which facilitates the translocation of a selective subset of gut bacteria to extraintestinal tissues to promote optimal antitumor T cell responses in both the tumor-draining lymph nodes (TDLNs) and the primary tumor. Antibiotic treatment results in decreased gut microbiota translocation into mesenteric lymph nodes (MLNs) and TDLNs, diminished DC and effector CD8+ T cell responses, and attenuated responses to ICT. Our findings illuminate a key mechanism by which gut microbiota promote extraintestinal anticancer immunity. Description Immune checkpoint blockade therapy induces gut bacteria translocation into secondary lymphoid organs and promotes extraintestinal antitumor immunity. Gut microbiota and immune checkpoint blockade Recent studies have suggested that the gut microbiome influences responses to immune checkpoint therapy (ICT) for cancer, but the mechanisms driving these responses are not clear. Choi et al. analyzed the translocation of specific endogenous bacteria from the gut to secondary lymphoid organs or melanoma tumors in a murine model. They observed translocation of some bacterial species during ICT enhanced dendritic cell activation and lymph node remodeling. These enhanced responses promoted antitumor T cell responses in tumor -raining lymph nodes and subcutaneous tumors. In contrast, antibiotic treatment diminished gut microbe translocation to draining lymph nodes and attenuated antitumor responses mediated by ICT. These findings provide critical insight into the role of gut microbe translocation in enhancing the effects of ICT. —CNF

[1]  R. Weissleder,et al.  Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. , 2022, Immunity.

[2]  T. D. de Gruijl,et al.  Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation , 2022, Science Immunology.

[3]  R. Rodrigues,et al.  Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment , 2021, Cell.

[4]  M. Konopleva,et al.  Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy , 2021, Blood advances.

[5]  Juliel Espinosa,et al.  Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy , 2021, Science.

[6]  G. Zeller,et al.  Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. , 2021, Cell host & microbe.

[7]  T. Cloughesy,et al.  Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma , 2021, Nature Communications.

[8]  M. Hurwitz,et al.  Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma , 2021, Journal of Clinical Oncology.

[9]  T. Lawrence,et al.  NF-κB–dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity , 2021, Science Immunology.

[10]  C. Mackay,et al.  Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity. , 2021, Cell metabolism.

[11]  J. Badger,et al.  Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients , 2021, Science.

[12]  N. Ajami,et al.  Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade , 2020, Nature Medicine.

[13]  N. Ajami,et al.  Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients , 2020, Science.

[14]  Z. Szallasi,et al.  Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage , 2020, Science.

[15]  K. McCoy,et al.  Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy , 2020, Science.

[16]  Noam Shental,et al.  The human tumor microbiome is composed of tumor type–specific intracellular bacteria , 2020, Science.

[17]  M. Suarez‐Almazor,et al.  Immune-related adverse events of checkpoint inhibitors , 2020, Nature Reviews Disease Primers.

[18]  J. Farkas Immune-related adverse events of checkpoint inhibitors , 2020, Nature Reviews Disease Primers.

[19]  Rob Knight,et al.  Microbiome analyses of blood and tissues suggest cancer diagnostic approach , 2020, Nature.

[20]  J. Gommerman,et al.  Dendritic Cell Subsets in Intestinal Immunity and Inflammation , 2020, The Journal of Immunology.

[21]  B. Comin-Anduix,et al.  Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist , 2020, Nature Communications.

[22]  E. Wakeland,et al.  Transcriptional profiling identifies caspase-1 as a T cell–intrinsic regulator of Th17 differentiation , 2020, The Journal of experimental medicine.

[23]  D. Altmann,et al.  Antibiotic therapy and outcome from immune-checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.

[24]  D. Goodlett,et al.  The Role of TLRs in Anti-cancer Immunity and Tumor Rejection , 2019, Front. Immunol..

[25]  C. Brock,et al.  Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. , 2019, JAMA oncology.

[26]  S. Turner,et al.  Microbiota-Derived Short-Chain Fatty Acids Promote the Memory Potential of Antigen-Activated CD8+ T Cells. , 2019, Immunity.

[27]  M. Gilmore,et al.  Mechanisms and consequences of gut commensal translocation in chronic diseases , 2019, Gut microbes.

[28]  V. Badovinac,et al.  Cutting Edge: Polymicrobial Sepsis Has the Capacity to Reinvigorate Tumor-Infiltrating CD8 T Cells and Prolong Host Survival , 2019, The Journal of Immunology.

[29]  E. Ruppin,et al.  Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice , 2019, Nature Communications.

[30]  K. Bélanger,et al.  Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors , 2019, Oncoimmunology.

[31]  K. Crozat,et al.  Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How? , 2019, Front. Immunol..

[32]  Amy Holt,et al.  The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant , 2019, Scientific Reports.

[33]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[34]  Ralph Weissleder,et al.  Successful Anti‐PD‐1 Cancer Immunotherapy Requires T Cell‐Dendritic Cell Crosstalk Involving the Cytokines IFN‐&ggr; and IL‐12 , 2018, Immunity.

[35]  A. Chan,et al.  Gastrointestinal Perforation after Rituximab Therapy in Mantle Cell Lymphoma: A Case Report , 2018, Case Reports in Oncology.

[36]  L. Massuger,et al.  Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report , 2018, Front. Oncol..

[37]  N. Salzman,et al.  Ceftriaxone Administration Disrupts Intestinal Homeostasis, Mediating Noninflammatory Proliferation and Dissemination of Commensal Enterococci , 2018, Infection and Immunity.

[38]  Alaina Kaiser,et al.  Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. , 2018, Blood.

[39]  Kaushal Parikh,et al.  Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors , 2018, Oncoimmunology.

[40]  T. Colpitts,et al.  Type 1 IFN and PD-L1 Coordinate Lymphatic Endothelial Cell Expansion and Contraction during an Inflammatory Immune Response , 2018, The Journal of Immunology.

[41]  S. Loi,et al.  Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3− Cell–Mediated Modulation of CD103+ Dendritic Cells , 2018, Cancer Immunology Research.

[42]  L. Zitvogel,et al.  Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  Konomi Ohshio,et al.  Characterization of genomic DNA of lactic acid bacteria for activation of plasmacytoid dendritic cells , 2018, bioRxiv.

[44]  Laurence Zitvogel,et al.  Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.

[45]  E. Le Chatelier,et al.  Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.

[46]  Riyue Bao,et al.  The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.

[47]  E. Frenkel,et al.  Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients , 2017, Neoplasia.

[48]  A. Eggermont,et al.  Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  T. Gajewski,et al.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.

[50]  Zhijian J. Chen,et al.  cGAS is essential for the antitumor effect of immune checkpoint blockade , 2017, Proceedings of the National Academy of Sciences.

[51]  Scott N. Mueller,et al.  Infection Programs Sustained Lymphoid Stromal Cell Responses and Shapes Lymph Node Remodeling upon Secondary Challenge. , 2017, Cell reports.

[52]  P. Rosenstiel,et al.  Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. , 2016, Immunity.

[53]  Matthieu Texier,et al.  Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination , 2016, Nature Reviews Clinical Oncology.

[54]  B. Hall,et al.  Tumor Induced Stromal Reprogramming Drives Lymph Node Transformation , 2016, Nature Immunology.

[55]  G. Núñez,et al.  Gut Microbiota-Induced Immunoglobulin G Controls Systemic Infection by Symbiotic Bacteria and Pathogens. , 2016, Immunity.

[56]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[57]  Jason B. Williams,et al.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.

[58]  M. Valsecchi Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[59]  Xiaowei Zhan,et al.  Activation of HIF-1α and LL-37 by commensal bacteria inhibits Candida albicans colonization , 2015, Nature Medicine.

[60]  Xiu-chun Yu,et al.  Postoperative infection and survival in osteosarcoma patients: Reconsideration of immunotherapy for osteosarcoma. , 2015, Molecular and clinical oncology.

[61]  G. Reynolds,et al.  Dendritic Cell Maturation and Survival Are Differentially Regulated by TNFR1 and TNFR2 , 2014, The Journal of Immunology.

[62]  Taro Kawai,et al.  Toll-Like Receptor Signaling Pathways , 2014, Front. Immunol..

[63]  Eric Vivier,et al.  The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide , 2013, Science.

[64]  Jaykaran Charan,et al.  How to calculate sample size in animal studies? , 2013, Journal of pharmacology & pharmacotherapeutics.

[65]  D. Littman,et al.  Microbiota Restrict Trafficking of Bacteria to Mesenteric Lymph Nodes by CX3CR1hi Cells , 2013, Nature.

[66]  R. Vance,et al.  Lethal inflammasome activation by a multi-drug resistant pathobiont upon antibiotic disruption of the microbiota , 2012, Nature Medicine.

[67]  L. Peyrin-Biroulet,et al.  Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease , 2011, Gut.

[68]  N. Socci,et al.  Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. , 2010, The Journal of clinical investigation.

[69]  U. Hobohm,et al.  Pathogen-associated molecular pattern in cancer immunotherapy. , 2008, Critical reviews in immunology.

[70]  A. Ruddell,et al.  Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. , 2007, The American journal of pathology.

[71]  R. Steinman,et al.  Differential Antigen Processing by Dendritic Cell Subsets in Vivo , 2007, Science.

[72]  E. Ekland,et al.  Regulation of lymph node vascular growth by dendritic cells , 2006, The Journal of experimental medicine.

[73]  R. Mebius Faculty Opinions recommendation of B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. , 2006 .

[74]  A. Macpherson,et al.  Mesenteric lymph nodes at the center of immune anatomy , 2006, The Journal of experimental medicine.

[75]  F. Ginhoux,et al.  B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. , 2006, Immunity.

[76]  H. Kiyono,et al.  CCR7 Is Critically Important for Migration of Dendritic Cells in Intestinal Lamina Propria to Mesenteric Lymph Nodes1 , 2006, The Journal of Immunology.

[77]  M. Festing Design and statistical methods in studies using animal models of development. , 2006, ILAR journal.

[78]  C. A. Kuntz,et al.  Improved Survival Associated With Postoperative Wound Infection in Dogs Treated With Limb-Salvage Surgery for Osteosarcoma , 2005, Annals of Surgical Oncology.

[79]  Jianping Pan,et al.  Interferon-γ is an autocrine mediator for dendritic cell maturation , 2004 .

[80]  A. Macpherson,et al.  Induction of Protective IgA by Intestinal Dendritic Cells Carrying Commensal Bacteria , 2004, Science.

[81]  U. Höpken,et al.  The chemokine receptor CCR7 controls lymph node‐dependent cytotoxic T cell priming in alloimmune responses , 2004, European journal of immunology.

[82]  J. Aitchison,et al.  Biplots of Compositional Data , 2002 .

[83]  Steffen Jung,et al.  In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. , 2002, Immunity.

[84]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[85]  A. Galy,et al.  IL-1β induces dendritic cells to produce IL-12 , 2001 .

[86]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[87]  Scott F. Smith,et al.  Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. , 1994, Science.

[88]  Kristin A. Hogquist,et al.  T cell receptor antagonist peptides induce positive selection , 1994, Cell.

[89]  J. Delaney,et al.  Abdominal radiation causes bacterial translocation. , 1989, The Journal of surgical research.

[90]  S. Schantz,et al.  Improved Survival Associated with Postoperative Wound Infection in Laryngeal Cancer: An Analysis of Its Therapeutic Implications , 1980, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.